Aspirin dosing for atherosclerotic cardiovascular disease: should we be more ADAPTABLE?

[1]  A. Siegbahn,et al.  Differential effect of clopidogrel and ticagrelor on leukocyte count in relation to patient characteristics, biomarkers and genotype: a PLATO substudy , 2021, Platelets.

[2]  James R. Campbell,et al.  Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease. , 2021, The New England journal of medicine.

[3]  R. Storey,et al.  Antithrombotic therapy for patients with chronic coronary syndromes , 2020, Heart.

[4]  W. Parker,et al.  Aspirin after PCI: in the twilight of its years? , 2020, Platelets.

[5]  S. Yusuf,et al.  Efficacy and safety of rivaroxaban plus aspirin in women and men with chronic coronary or peripheral artery disease. , 2020, Cardiovascular research.

[6]  D. Voora,et al.  Genetic influences on aspirin response in patients undergoing percutaneous coronary intervention. , 2019, Cardiovascular research.

[7]  R. Storey,et al.  Very-low-dose twice-daily aspirin maintains platelet inhibition and improves haemostasis during dual-antiplatelet therapy for acute coronary syndrome , 2019, Platelets.

[8]  E. Grove,et al.  Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis. , 2018, European heart journal.

[9]  C. Patrono,et al.  On‐pump Cardiac Surgery Enhances Platelet Renewal and Impairs Aspirin Pharmacodynamics: Effects of Improved Dosing Regimens , 2017, Clinical pharmacology and therapeutics.

[10]  C. Patrono.  Aspirin as an antiplatelet drug. , 1994, The New England journal of medicine.